$HRTX

Heron sets May 11 webcast for Q1 results and business updates

Heron Therapeutics (Nasdaq: HRTX) announced it will report its first-quarter 2026 financial results and discuss business highlights on Monday, May 11, 2026, at 8:30 a.m. ET. The event will include a conference call and live webcast accessible through registration on the company's investor relations website, where an archive will also be available for 60 days. Investors are advised to register and dial in 15 minutes early to avoid delays.

Original reporting
Published Apr 27, 2026, 9:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 27, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Heron sets May 11 webcast for Q1 results and business updates — source image
Decision brief

The 30-second read

$HRTXNeutralMed
01

Why it matters

Earnings results are likely to influence short-term trading activity, with the possibility of increased volatility around the event.

02

Market read

The event is highly relevant for investors and traders focusing on biotech and life sciences sectors, with potential ripple effects on related stocks.

03

What to watch

Potential regulatory developments or pipeline updates could overshadow earnings results and influence stock movement.

Timing: High, as the event is scheduled for May 11, 2026, and traders can position accordingly.

Background

Heron Therapeutics specializes in developing and commercializing therapies for cancer and other serious conditions. The upcoming earnings report will provide insights into its financial health and pipeline progress.

Company-level read

Ticker impact

$HRTXNeutralMedium confidence
Context

The upcoming Q1 2026 earnings report is a significant event for Heron Therapeutics, potentially impacting the stock's short-term price movement.

Expected impact

Potential for increased volatility around the event; stock may experience a short-term move in either direction depending on results and guidance.

Evidence & confidence

Earnings reports typically lead to increased trading activity; however, without current stock price and analyst consensus data, the precise impact remains uncertain.

Market effects

Positive earnings could boost investor confidence in the biotech/life sciences sector, potentially lifting sector indices.

Limited regional impact; primarily affecting US-based biotech stocks.

Minimal, unless results significantly outperform or underperform expectations, influencing global biotech sentiment.

Counterpoint

Disappointing earnings or guidance could lead to a sharp decline, suggesting caution in overly optimistic positioning.

Key entities

  • Heron Therapeutics

    A biotech company focused on cancer and other serious conditions.

Related articles

$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-yea

$NVDAMed

Nvidia teams up with Wall Street asset managers on $500 billion AI infrastructure push

CNBC reports Nvidia is working with Apollo, Blackstone, BlackRock’s Global Infrastructure Partners, Brookfield, Goldman Sachs and KKR on a planned $500 billion financing push for AI infrastructure, citing an unnamed source. An announcement could come as soon as Monday, according to the report. The effort would help customers finance Nvidia GPUs and data centers, including power capacity needs.

$ARTWMed

Art's-Way Manufacturing Co.: Art's Way Announces Significant Increase in Backlog Following Award of Major Modular Building Projects

Art's-Way Manufacturing Co. (Nasdaq:ARTW) said its Modular Buildings segment backlog rose to over $19.0 million after winning major modular building projects. The company cited a prior $1.3 million backlog in its May 31, 2026 10-Q. It expects fulfillment by end of fiscal 2027, subject to schedules and milestones, with margins generally consistent with historical performance.